More about

Car T-Cell Therapy

News
October 17, 2022
7 min read
Save

Cell therapy pioneer: Modality could be solution to ‘pretty large cadre’ of diseases

Cell therapy pioneer: Modality could be solution to ‘pretty large cadre’ of diseases

The basic science discoveries to which Helen E. Heslop, MD, DSc (Hon), has contributed place her firmly on the Mount Rushmore of pioneers in the field of gene and cell therapy.

News
October 04, 2022
6 min read
Save

CAR-T has ‘fundamentally changed’ outcomes in follicular lymphoma

CAR-T has ‘fundamentally changed’ outcomes in follicular lymphoma

Follicular lymphoma is among the least common types of non-Hodgkin lymphoma, but the nature of the disease has allowed those who require treatment to benefit from the groundbreaking development of chimeric antigen receptor T cells.

News
October 03, 2022
1 min read
Save

FDA grants orphan drug designation to CAR-T for acute myeloid leukemia

FDA grants orphan drug designation to CAR-T for acute myeloid leukemia

The FDA granted orphan drug designation to KITE-222, an investigational chimeric antigen receptor T-cell therapy, for treatment of adults with relapsed or refractory acute myeloid leukemia.

News
September 29, 2022
1 min read
Save

FDA grants orphan drug designation to CAR-T for mesothelioma

FDA grants orphan drug designation to CAR-T for mesothelioma

The FDA granted orphan drug designation to SynKIR-110, an investigational chimeric antigen receptor T-cell therapy, for treatment of mesothelin-expressing mesothelioma.

News
September 28, 2022
3 min read
Save

Novel CAR-T effective for most patients with advanced multiple myeloma

Novel CAR-T effective for most patients with advanced multiple myeloma

A chimeric antigen receptor T-cell therapy produced a response rate of 71% among patients with relapsed or refractory multiple myeloma, according to phase 1 study results published in The New England Journal of Medicine.

News
August 31, 2022
3 min read
Save

Immune environment may dictate durability of response to CAR-T for multiple myeloma

Immune environment may dictate durability of response to CAR-T for multiple myeloma

Prolonged responses to chimeric antigen receptor T-cell therapy for advanced multiple myeloma may depend on the composition of the patient’s post-treatment immune microenvironment, results from a retrospective study showed.

News
August 30, 2022
4 min read
Save

CAR-T will ‘play a very important role’ in multiple myeloma treatment landscape

CAR-T will ‘play a very important role’ in multiple myeloma treatment landscape

The FDA approval of the first ever chimeric antigen receptor T-cell therapy for multiple myeloma in 2021 laid the groundwork for others to follow.

News
August 29, 2022
6 min read
Save

Triple-class refractory multiple myeloma a ‘launching pad’ for groundbreaking therapies

Triple-class refractory multiple myeloma a ‘launching pad’ for groundbreaking therapies

The last few years have seen major therapeutic advancements in the field of triple-class refractory multiple myeloma.

News
August 29, 2022
2 min read
Save

Regional disparities affect Black patients’ access to immunotherapy clinical trials

Regional disparities affect Black patients’ access to immunotherapy clinical trials

Unequal distribution of trial sites nationwide has led to inequitable access to cutting-edge immunotherapies among Black patients with advanced multiple myeloma, according to research published in JAMA Network Open.

News
August 25, 2022
4 min read
Save

‘Basic’ research leads to potential breakthrough to enhance CAR-T for solid tumors

‘Basic’ research leads to potential breakthrough to enhance CAR-T for solid tumors

Researchers who identified proteins that influence T-cell formation have leveraged their discovery to develop a process that boosts the efficacy of chimeric antigen receptor T-cell therapy for solid tumors.

View more